HotSheets 2013  

January - March | April - June | July - September | October - December

 

January   | View Newsletter

February    | View Newsletter

March   | View Newsletter

  • FDA Expands Zytiga’s Use for Late-Stage CRPC Prior to Chemotherapy
  • Adding Testosterone to Sildenafil Does Not Benefit Men with Erectile Dysfunction
  • Aerobic Exercise Eases Fatigue in Patients with Breast and Prostate Cancer
  • Diagnostic Performance of PCA3 for Detecting Prostate Cancer in Men with an Elevated PSA
  • Phase II Study of Cabozantinib in Men with Advanced Prostate Cancer
  • Doc Moyad’s “No Bogus Science” Column – “What Has 150 Calories & Stifles Weight
  • Ask Doctor Snuffy Myers
  • Doctor Chodak’s Bottom Line
  • Index of Articles Published in 2012 HotSheets
  • Protons for Prostate Cancer: Fleeting Quality of-Life Benefits
  • Updated Partin Tables Now Available
  • Radium-223 New Drug Application Submitted
  • Cost of Prostate Cancer Treatments Compared
  • Do Genetic Markers Improve Prostate Cancer Risk Prediction After an Initial Negative Biopsy?
  • Targeted Prostate Biopsy May Improve Care
  • 2-Weekly Vs. 3-Weekly Docetaxel
  • Association of Adiponectin & Leptin with Stage & Grade of PSA-Detected Prostate Cancer
  • Be Prepared, by Ray Marsh, Us TOO, UK
  • Antioxidants – the Enemy in Cancer Treatment?
  • Ask Doctor Snuffy Myers
  • Doc Moyad’s “No Bogus Science” Column – “Is It Time to Discuss Metformin with Your MD?”
  • Doctor Chodak’s Bottom Line
  • Similar Function after Surgery & Radiation
  • ‘Smarter’ PSA Testing Strategies Proposed
  • REDUCE Study & Rates of Prostate Cancer
  • 10-Year Oncologic Outcomes after Low Dose Rate Brachytherapy for Prostate Cancer
  • Low Neutrophil Count & Prostate Biopsies
  • Regaining Continence After Prostate Surgery
  • Identification Errors in Prostate Biopsies
  • Prostatectomy Outcomes in Low-Risk Cancer
  • T2–Diffusion-Weighted MRI & Adverse Post-prostatectomy Pathologic Outcome
  • High Fiber Diet & Prostate Cancer Progression
  • Ask Doctor Snuffy Myers
  • Doc Moyad’s “No Bogus Science” Column – “Exercise & Statins & Prostate Cancer Death”
 
 

April   | View Newsletter

May   | View Newsletter

June   | View Newsletter

  • Shorter ADT Duration Ok in High-Risk Cancer
  • Prostate Cancer Overtreatment Costs $32M
  • Updated Survival Benefits with Abiraterone
  • Prostate Health Index vs. PCA-3 Urine Test
  • 25-Year Survival Rate After Irradiation
  • Identifying Prostate Cancer by Changes in PSA
  • Male-Pattern Baldness & Prostate Cancer Risk
  • Doc Moyad’s “No Bogus Science” Column – “More About Mediterranean Diets”
  • Ask Doctor Snuffy Myers
  • Clues Found to Prostate Cancer Upgrading
  • Long-Term RT Outcomes in Men Under 60
  • Dasatinib Fails in Phase III CRPC Trial
  • Doctor Chodak’s Bottom Line
  • Intermittent Hormone Treatment for Prostate Cancer Not the Best
  • Additional Role for Abiraterone in CRPC
  • Degarelix Showing Promise in Prostate Cancer
  • Long-Term PSA Velocity in Improved Classifi-cation of Prostate Cancer Risk & Mortality
  • Benign Glandular Tissue at Radica
  • Prostatectomy Surgical Margins
  • Doc Moyad’s “No Bogus Science” Column – “End of the Line for High-Dose Selenium”
  • Richard Petty Teams Up With Janssen Biotech to Launch “Show Your Stripes for Prostate Cancer Awareness”
  • Congressionally Directed Medical Research Programs Research Funding for 2013
  • Doctor Chodak’s Bottom Line
  • AUA & ASTRO Issue Joint Guideline for Postsurgery Radiotherapy
  • New AUA Guideline for Castrate-Resistant Prostate Cancer
  • AUA Issues New Guidelines on PSA Screening
  • Cancer Immunotherapy: An Overview
  • Doc Moyad’s “No Bogus Science” Column – “Former Smokers – Beware of Beta-carotene”
  • High-Dose Radiotherapy: Better Local Con-trol, Not Survival
  • Gene Test For Prostate Cancer Shows Promise
  • Midlife PSA Test Predicts Future Prostate Cancer Risk
  • Doctor Chodak’s Bottom Line
 
 

July   | View Newsletter

August   | View Newsletter

September   | View Newsletter

  • Xofigo (Radium-223) Approved for Prostate Cancer with Bone Metastases
  • Prostate Cancer with Faulty BRCA2 Gene Spreads More Quickly
  • How Likely Is Prostate Cancer To Kill?
  • Itraconazole vs. Advanced Prostate Cancer
  • Can A Gene Test Predict Prostate Cancer?
  • Doc Moyad’s “No Bogus Science” Column – “Vitamin C Can Cause Kidney Stones”
  • New AUA Guidelines on PSA Screening
  • Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • June is Men’s Health Month
  • Enzalutamide in Advanced, Hormone Naïve Prostate Cancer Reduces PSA
  • Doctor Chodak’s Bottom Line
  •  Active Surveillance May Miss Aggressive Prostate Cancers in Black Men
  • Advanced Treatment Technologies for Men with Low Risk Prostate Cancer
  • Observation – Better Efficacy, Cost, QoL
  • Cross-resistance with Novel Androgen Blockers in Prostate Cancer
  • Doc Moyad’s “No Bogus Science” Column – Fish Oil Flops in 2012-2013 Research”
  • Heart-Healthy Diet May be Healthy for Prostate Cancer
  • Brisdelle Okayed as First Nonhormonal Treatment for Hot Flashes
  • Expanding Active Surveillance Criteria
  • 5-alpha Reductase Inhibitors for LUTS and Prevention of Prostate Cancer
  • Doctor Chodak’s Bottom Line
  • Metformin & Prostate Cancer Mortality
  • Stop Calling Low-Risk Lesions Cancer
  • Ketoconazole & Fatal Liver Toxicity
  • Taxotere + 153Samarium for CRPC
  • Defining A Castrate Testosterone Level
  • Endurance Training for ADT-Weight Gain
  • Doc Moyad's "No Bogus Science" Column – "Obesity Deaths Have Been Underestimated"
  • GAO Targets Self-Referrals for RT
  • Risk of Kidney Injury from ADT?
  • Soy Fails to Slow PSA Rise after RP
  • Doctor Chodak's Bottom Line
 
 

October   | View Newsletter

November   | View Newsletter

December   | View Newsletter

  • Insurers Nix Payment for Proton Beam Radiation Treatment for Prostate Cancer
  • Chemoprevention for Prostate Cancer
  • Low-Grade Prostate Cancers Don’t Worsen
  • Testosterone Therapy Does Not Raise Prostate Cancer Recurrence Risk
  • Effect of Repeated Prostate Biopsies on Erectile Function During Active Surveillance
  • Mortality in Men Treated by RP, EBRT and BT Mortality without Comorbid Illness
  • American Cancer Society Ends Man-2-Man
  • 15th Annual Us TOO Walk & Run
  • Doc Moyad’s “No Bogus Science” Column - “Resveratrol is a Waste of Money”
  • Laparoscopic Prostatectomy in Obese Men
  • Doctor Chodak’s Bottom Line
  • Fewer Weeks of Hormone Therapy before Radiation Reduces Side Effects
  • PSA Screening Does More Harm than Good
  • Drugs for Female Hot Flashes Don’t Help Men
  • Herbal Products Often Contain Contaminants
  • CRPC Responds to Abiraterone Withdrawal
  • Disability Benefits and Prostate Cancer
  • Commercial Urine Test for Prostate Cancer Available from University of Michigan Labs
  • 30-Year Outcomes for Men with Positive Lymph Nodes at Radical Prostatectomy
  • Doc Moyad’s “No Bogus Science” Column – “Abiraterone, Prednisone and Potassium”
  • The Melbourne Consensus Statement Clarifies the Confusion around PSA Screening
  • Enzalutamide Meets Study Endpoints of Overall and Metastatic Progression-Free Survival
  • Prostate Cancer Tops in Inheritable Cancers
  • Ways to Boost Enrollment in Clinical Trials
  • Elastography-Targeted Prostate Biopsies
  • PSA <1 ng/mL in Men in Their 40’s Associated with a Very Low Risk of Prostate Cancer
  • Origins of Lethal Prostate Cancer Traced
  • Clinical Benefits of Non-Taxane Chemotherapy for CRPC after Progression on Docetaxel
  • Testosterone Treatment Linked to Heart Risks
  • Doc Moyad’s “No Bogus Science” Column – “Colored Fruits and Veggies and Health”
 
 

Facebook - UsToo.org  Twitter - UsToo.org  LinkedIn - UsToo.org Inspire prostate cancer discussions – UsToo.org 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

 
Copyright © 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.